Pathalys Pharma, a Research Triangle Park, NC-based biopharmaceutical company in the late stages of developing treatments for kidney disease, raised $105M in Series B funding.
The round was led by TCGX, which was joined by other investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.
The company intends to use the funds to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations.
Pathalys Pharma is a late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of ESKD. Its initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, the company continues to identify other needs and potential solutions for patients with ESKD.
FinSMEs
20/08/2024